Clinical Trial

A Study of E6742 in Participants With Systemic Lupus Erythematosus

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The main purpose of the study is to demonstrate the efficacy based on dose response of E6742 compared with placebo as defined by the proportion of participants achieving a response using the British Isles Lupus Assessment Group (BILAG) based Composite Lupus Assessment (BICLA) with a low dose of oral corticosteroids (OCS) (prednisone or equivalent) at Week 24 in participants with systemic lupus erythematosus (SLE).
Protocol Amendment History 5 changes
notable Trial sites expanded: 28 -> 41 locations 2026-07-03
notable Trial sites expanded: 22 -> 28 locations 2026-06-26
notable Trial sites expanded: 17 -> 22 locations 2026-06-05
critical Recruitment opened 2026-04-29
notable Trial sites expanded: 2 -> 17 locations 2026-04-29
Trial Details
NCT Number NCT07515014
Lead Sponsor Eisai Co., Ltd.
Conditions Systemic Lupus Erythematosus
Enrollment 256 participants
Start Date 2026-03-31
Primary Completion 2028-08-05 (estimated)
Study Completion 2029-03-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-02